The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat

Xenobiotica

Volumn 37, Issue 3, 2007, Pages 298-314

  Treiber, A ^a   Morand, O ^a   Clozel, M ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Brain penetration; Gaucher disease; Miglustat; Pharmacokinetics; Tissue distribution; Zavesca

Indexed keywords

CARBON 14; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; MIGLUSTAT; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; EXPERIMENTAL STUDY; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; GLOMERULUS FILTRATION; ISOTOPE LABELING; KIDNEY CLEARANCE; LIVER CLEARANCE; LONG TERM CARE; LUNG FUNCTION; MALE; NONHUMAN; RAT; TISSUE DISTRIBUTION;

1-DEOXYNOJIRIMYCIN; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; ENZYME INHIBITORS; FEMALE; GLUCOSYLTRANSFERASES; INJECTIONS, INTRAVENOUS; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRITIUM;

RATTUS;

EID: 33947314170     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601094543     Document Type: Article

References (23)

1. Accardo AP, Pensiero S, Perissutti P. 2005. Saccadic analysis for early identification of neurological involvement in Gaucher disease. Annals of the New York Academy of Sciences 1039:503-507.
2. Beutler E. 2004. Enzyme replacement in Gaucher disease. PLoS medicine, 1, e21.
3. Beutler E. 2006. Gaucher disease: Multiple lessons from a single gene disorder. Acta Paediatrica. Supplementum 95:103-109.
4. Beutler E, Kuhl W, Vaughan LM. 1995. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages. Molecular Medicine 1:320-324.
5. Butters TD, Dwek RA, Platt FM. 2005. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15:43R-52R.
6. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, et al. 2000. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481-1485.
7. Elstein D, Guedalia J, Doniger GM, Simon ES, Antebi V, Arnon Y, Zimran A. 2005. Computerized cognitive testing in patients with type I Gaucher disease: Effects of enzyme replacement and substrate reduction. Genetics in Medicine 7:124-130.
8. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, et al. 2004. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. Journal of Inherited Metabolic Disease 27:757-766.
9. Grosman ME, Elias MM, Comin EJ, Rodriguez Garay EA. 1983. Alterations in renal function induced by aflatoxin B1 in the rat. Toxicology and Applied Pharmacology 69:319-325.
10. Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, Elstein D. 2004. Bone density changes with enzyme therapy for Gaucher disease. Journal of Bone and Mineral Metabolism 22:597-601.
11. Mankin HJ, Trahan CA, Barnett NA, Laughead J, Bove CM, Pastores GM. 2006. A questionnaire study for 128 patients with Gaucher disease. Clinical Genetics 69:209-217.
12. Mercimek-Mahmutoglu, S. 2004. Unpublished results; data presented at SSIEM, Amsterdam.
13. Pastores GM, Barnett NL, Bathan P, Kolodny EH. 2003. A neurological symptom survey of patients with type I Gaucher disease. Journal of Inherited Metabolic Disease 26:641-645.
14. Pastores GM, Barnett NL, Kolodny EH. 2005. An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment. Clinical Therapeutics 27:1215-1227.
15. Perretti A, Parenti G, Balbi P, Titomanlio L, Marcantonio L, Iapoce M, Frascogna AR, Andria G, Santoro L. 2005. Study of multimodal evoked potentials in patients with type 1 Gaucher's disease. Journal of Child Neurology 20:124-128.
16. Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD. 2003. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 358:947-954.
17. Priestman DA, Platt FM, Dwek RA, Butters TD. 2000. Imino sugar therapy for type 1 Gaucher disease. Glycobiology 10:iv-vi.
18. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. Journal of Pharmaceutical Sciences 94:1259-1276.
19. Rudzki Z, Okon K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. 2003. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - A histological study. European Journal of Haematology 70:273-281.
20. Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI. 2002. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells, Molecules and Diseases 28:288-296.
21. Sidransky E. 2005. Gaucher disease and parkinsonism. Molecular Genetics and Metabolism 84:302-304.
22. Yang SK, Hsieh YY, Chang WC, Huang JD. 1992. Enantioselectivity of microsomal and cytosolic esterases in rat intestinal mucosa. Drug Metabolism and Disposition 20:719-725.
23. Zimran A, Elstein D. 2003. Gaucher disease and the clinical experience with substrate reduction therapy. Philosophical transactions of the Royal Society of London. Series B, Biological Sciences 358:961-966.